Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.18 ^USD	-6.35%		0.00%	+114.55%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Apr. 01	Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 12, 2022 at 07:41 am EDT

Xilio Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 21.35 million compared to USD 16.67 million a year ago. Basic loss per share from continuing operations was USD 0.78 compared to USD 23.53 a year ago. Diluted loss per share from continuing operations was USD 0.78 compared to USD 23.53 a year ago.

Latest news about Xilio Therapeutics, Inc.

Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	Apr. 19	MT
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Top Midday Gainers	Apr. 01	MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Top Premarket Gainers	Apr. 01	MT
Xilio Shares Take Flight Premarket After Gilead Deal	Mar. 28	DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12	Mar. 28	MT
Transcript : Xilio Therapeutics, Inc. - Special Call	Mar. 28
Xilio Therapeutics Plans Private Placement, Job Cuts	Mar. 28	DJ
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program	Mar. 28	DJ
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc	Mar. 28	CI
Xilio Therapeutics, Inc. Plans Workforce Reduction	Mar. 28	CI
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202	Mar. 28	CI
Xilio Therapeutics, Inc. announced that it expects to receive $11.3 million in funding	Mar. 27	CI
Xilio Therapeutics, Inc. Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101	Dec. 07	CI
Xilio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Xilio Therapeutics, Inc. - Special Call	Nov. 06
Xilio Therapeutics Shares Rise Following Initial Phase 1/2 Data on XTX202	Nov. 03	MT
Xilio Therapeutics, Inc. Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202	Nov. 03	CI
Transcript : Xilio Therapeutics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 02:55 PM	23-09-11
Xilio Therapeutics Announces Board Changes	23-09-05	CI
Transcript : Xilio Therapeutics, Inc. - Special Call	23-08-17

Chart Xilio Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.18 USD

Average target price

4.667 USD

Spread / Average Target

+295.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XILIO THERAPEUTICS, INC.	+114.55%	43.55M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research